Evidence map›Paper›PMID 37298413›Full record

ArticleInternational journal of molecular sciences2023

Transcriptome-Wide Analysis of Low-Concentration Exposure to Bisphenol A, S, and F in Prostate Cancer Cells.

Sergio A Cortés-Ramírez, Ana M Salazar, Monserrat Sordo, Patricia Ostrosky-Wegman, Miguel Morales-Pacheco, Marian Cruz-Burgos, Alberto Losada-García, Griselda Rodríguez-Martínez, Imelda González-Ramírez, Karla Vazquez-Santillan and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sergio A Cortés-RamírezLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0002-5967-0768
Ana M SalazarInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Mexico City 70228, Mexico.
Monserrat SordoInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Mexico City 70228, Mexico.
Patricia Ostrosky-WegmanInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Mexico City 70228, Mexico.ORCID 0000-0002-8564-3472
Miguel Morales-PachecoLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0002-0701-980X
Marian Cruz-BurgosLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0003-3015-3836
Alberto Losada-GarcíaLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
Griselda Rodríguez-MartínezLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
Imelda González-RamírezDepartamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City 04960, Mexico.
Karla Vazquez-SantillanLaboratorio de Innovación en Medicina de Precisión, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0003-1380-2494
Vanessa González-CovarrubiasLaboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0003-2072-2847
Vilma Maldonado-LagunasLaboratorio de Epigenética, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0002-7254-5961
Mauricio Rodríguez-DorantesLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0003-4249-7222
National Institute of Genomic Medicine · MXUniversidad Nacional Autónoma de México · MXUniversidad Autónoma Metropolitana · MX

Funding

Consejo Nacional de Ciencia y Tecnología A1-S-26446
6 · The paper itself

Abstract

Bisphenol A (BPA) is a ubiquitous synthetic compound used as a monomer in the production of polycarbonate plastics and epoxy resins. Even at low doses, BPA has been associated with the molecular progression of diseases such as obesity, metabolic syndrome, and hormone-regulated cancers due to its activity as an endocrine-disrupting chemical (EDC). Consequently, the use of BPA has been regulated worldwide by different health agencies. BPA structural analogs such as bisphenol S and bisphenol F (BPS and BPF) have emerged as industrial alternatives, but their biological activity in the molecular progression of cancer remains unclear. Prostate cancer (PCa) is a hormone-dependent cancer, and the role of BPA structural analogs in PCa progression is still undescribed. In this work, we use an in vitro model to characterize the transcriptomic effect of low-concentration exposure to bisphenol A, S, or F in the two main stages of the disease: androgen dependency (LNCaP) and resistance (PC-3). Our findings demonstrated that the low concentration exposure to each bisphenol induced a differential effect over PCa cell lines, which marks the relevance of studying the effect of EDC compounds through all the stages of the disease.

Indexed as

Prostatic NeoplasmsTranscriptomeBenzhydryl CompoundsBisphenol A CompoundsCell LineHormonesHumansMaleBenzhydryl Compoundsbisphenol ABisphenol A CompoundsHormonesbioinformaticsDNA damageendocrine disrupting chemicalsprostate cancertranscriptome

Identifiers

PMID37298413
PMCPMC10253990
OpenAlexW4380225079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.